PARP1 and ovarian carcinoma: Combinations of PARP inhibitors with drugs that inhibit homologous recombination (HR) may sensitize epithelial ovarian cancers with primary or secondary HR proficiency to PARP inhibitors and potentially expand their use beyond HR-deficient ovarian cancers.